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Re: ‘Re. Efﬁcacy and Safety of the New Oral Anticoagulants
Dabigatran, Rivaroxaban, Apixaban, and Edoxaban in the
Treatment and Secondary Prevention of VTE: A Systematic
Review and Meta-analysis of Phase III Trials’
We would like to thank the authors of this letter for giving
us the opportunity to discuss some practical issues on the
use of NOAs in the management of VTE, which were not the
subject of our meta-analysis.1
We fully agree with the statement regarding the short
half-life and rapid onset of action of NOAs, which can be
discontinued and resumed rapidly pre- and post-operatively
for elective procedures, and that their use shortens the
window of risk for thromboembolism in patients treated for
either atrial ﬁbrillation or venous thromboembolism. These
are scenarios that are faced everyday in clinical practice; the
appropriate solution can be provided if the pharmacological
properties of the various NOAs are known.
We mentioned in the discussion section of our meta-
analysis the “different pharmacological properties, pharma-
codynamics, anticoagulation intensity, and dosing schedules of
the various agents.” These are recognized issues and the ﬁrst
two are the result of the different molecular structure of the
various NOAs. We would like to congratulate the authors for
making a table to compare these novel anticoagulants in terms
of mode of action and indication for use. We would like to
point out that for the treatment of venous thromboembolism
the recommended dose of rivaroxaban is 20 mg OD after the
ﬁrst 3 weeks of treatment. Similarly for apixaban, currently
approved to treat venous thromboembolism in the European
Union, the therapeutic dose is 5mgBD (10mgBD for theﬁrst 7
days). Continuous medical education is obviously extremely
important for all physicians and part of this is accomplished by
attending educational seminars and conferences run by pro-
fessional societies like I.S.E.T.A.T. (Institute For The Study And
Education On Thrombosis And Antithrombotic Therapy,
http://www.imetha.gr/EN/) in our country.
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of Early Recurrent Stroke: Importance of Cohort
Composition and Index Event Deﬁnition’
We read with interest the invited commentary of de Borst1
in response to our recent article on the risk of early
recurrent stroke in a population with symptomatic carotid
stenosis, and would like to take the opportunity to clarify a
few points.2
De Borst argues that we underestimate the actual risk
of recurrent stroke by deﬁning the index event as the
event that resulted in referral to hospital. We consider
that the alternative, to deﬁne the index event as the very
ﬁrst neurological event would risk overestimating the rate
of recurrence because the calculation/estimation/assess-
ment will not include all patients with an event without
neurological recurrence, who do not seek medical atten-
tion. Therefore, it is our view that a valid recurrence rate
can only be calculated from events occurring after a
Re: ‘The True Risk of Early Recurrent Stroke: Importance of
Cohort Composition and Index Event Deﬁnition’
In the individual patient with symptomatic signiﬁcant ca-
rotid artery stenosis there are two means of reducing the
overall risk of recurrent stroke: (i) by early recognition of
the presenting symptom and fast work up to perform
expedited carotid revascularization thus preventing recur-
rent events in the waiting time to surgery; and (ii) by per-
forming safe carotid revascularization.1,2
In recent years, in symptomatic patients with carotid
artery disease (CAD), the focus has been on early inter-
vention, to be performed as soon as possible but at least
within 2 weeks of presentation. To reach this 2 week
threshold and in order to score the effectiveness of the
center and specialist involved, the referral event is the
easiest and most practical starting point. However, in using
the referral event to assess the rate of recurrent events,
patients that suffered a recurrent stroke as secondary event
before referral may be missed, and as a consequence may
no longer be candidates for revascularization. These pa-
tients, with a second severe cerebral event prior to referral,
have been named “the lost cohort” as these patients are
often not included in studies on patients undergoing carotid
revascularization. By counting the very ﬁrst event as the
index event in patients with symptomatic CAD, it will be
possible to analyze the true risk of early recurrent stroke
and also include those that had their recurrent event prior
to referral. In doing so, the true impact of recurrent events
can become identiﬁable, and this has more relevance to the
overall prevention of stroke instead of reporting only the
events in patients scheduled for intervention.
The deﬁnitions “latest event”, “referral event”, or “most
recent event” all distract from what is most relevant to the
patient: recognition of the symptoms as being related to
severe CAD, needing urgent work up and expedited revas-
cularization. In order to protect as many patients as possible
it is therefore necessary to keep in mind that most recur-
rent events can be prevented when using the very ﬁrst
event as the index event for intervention. The clinical
128 Correspondencecommon time point where patients are identiﬁed, the
referral event.
This leads us to a second problem with deﬁnitions. As
indicated by de Borst, Rantner et al.3 recently reported that
acute carotid endarterectomy does not confer increased
procedural risk, in contrast to our earlier prospective anal-
ysis showing that very early carotid endarterectomy is
associated with increased risk.3 However, Rantner et al.3
deﬁned the index event as the latest event rather than
the event that resulted in referral, and we argue that this
difference could explain part of the discrepancy.4 Guidelines
state that patients seeking medical care for a neurological
event should receive immediate treatment with statins and
antiplatelet agents. A recent study showed that the risk of
recurrent stroke is lower in patients pre-treated with sta-
tins, and it is thus likely that the procedural risk is reduced
by medical treatment received in hospital.5 Thus, deﬁning
the index event as the most recent event may result in a
bias towards lower complication rates.
We agree that the beneﬁt with early (within 14 days)
carotid endarterectomy is proven. However, the advantage
of surgery within 2 days of a referring event is not clear and
could even be associated with higher risk than medical
treatment alone.
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